Ono Masahiro, Saji Hideo
Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan.
Int J Mol Imaging. 2011;2011:543267. doi: 10.1155/2011/543267. Epub 2011 Apr 13.
The development of radiotracers for use in vivo to image β-amyloid (Aβ) plaques in cases of Alzheimer's disease (AD) is an important, active area of research. The presence of Aβ aggregates in the brain is generally accepted as a hallmark of AD. Since the only definitive diagnosis of AD is by postmortem staining of affected brain tissue, the development of techniques which enable one to image Aβ plaques in vivo has been strongly desired. Furthermore, the quantitative evaluation of Aβ plaques in the brain could facilitate evaluation of the efficacy of antiamyloid therapies currently under development. This paper reviews the current situation in the development of agents for SPECT-based imaging of Aβ plaques in Alzheimer's brains.
开发用于体内成像阿尔茨海默病(AD)患者脑内β-淀粉样蛋白(Aβ)斑块的放射性示踪剂是一个重要且活跃的研究领域。脑内Aβ聚集体的存在通常被认为是AD的一个标志。由于AD的唯一确诊方法是对受影响的脑组织进行死后染色,因此人们一直强烈希望开发能够在体内对Aβ斑块进行成像的技术。此外,对脑内Aβ斑块进行定量评估有助于评估目前正在研发的抗淀粉样蛋白疗法的疗效。本文综述了用于阿尔茨海默病大脑中基于单光子发射计算机断层扫描(SPECT)成像Aβ斑块的药物的开发现状。